A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with
lazertinib or in combination with chemotherapy works (antitumor activity) in participants
with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC;
that is one of the major types of lung cancer).

Treatment Sites in Georgia